83417-26-9 Usage
General Description
5-(Pyridin-4-ylmethyl)-4H-1,2,4-triazol-3-amine, also known as PT130, is a chemical compound with the molecular formula C10H10N6. PT130 is a triazolyl-based derivative that has been studied for its potential as an antitumor and antiviral agent. It has been shown to have inhibitory effects on the metastasis and proliferation of cancer cells, as well as antiviral activity against HIV and HSV-1. PT130 has also been investigated for its potential as an anti-inflammatory and anti-fibrotic agent. Due to its promising pharmacological properties, PT130 is of interest for further research and development as a potential therapeutic agent for various diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 83417-26-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,3,4,1 and 7 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 83417-26:
(7*8)+(6*3)+(5*4)+(4*1)+(3*7)+(2*2)+(1*6)=129
129 % 10 = 9
So 83417-26-9 is a valid CAS Registry Number.
InChI:InChI=1/C8H9N5/c9-8-11-7(12-13-8)5-6-1-3-10-4-2-6/h1-4H,5H2,(H3,9,11,12,13)
83417-26-9Relevant articles and documents
Bioisosteric Design of Conformationally Restricted Pyridyltriazole Histamine H2-Receptor Antagonists
Lipinski, Christopher A.
, p. 1 - 6 (2007/10/02)
A process of bioisosteric drug design is described whereby, in a manner analogous to synthesis, key portions of an effector molecule are successively replaced by pharmacophores or bioisosteres.This process, when applied to histamine, leads to the competitive histamine H2-receptor antagonist prototype 3-amino-5-(2-amino-4-pyridyl)-1,2,4-triazole (7).The biaryl nature of 7 fixes internitrogen distances, and comparison of these with histamine suggests that 7 shares structural features more in common with histamine trans rather than histamine gauche conformations.Alkylation of the prototype pyridylamino group in 7 markedly improves both histamine H2-receptor antagonist and gastric acid antisecretory activity so that the resulting agent, 3-amino-5--1,2,4-triazole (8), is more active than cimetidine.
